The Discounted Cash Flow (DCF) valuation of Sorrento Therapeutics Inc (SRNE) is (43,208.66) USD. With the latest stock price at 0.31 USD, the upside of Sorrento Therapeutics Inc based on DCF is -14060843.3%.
Based on the latest price of 0.31 USD and our DCF valuation, Sorrento Therapeutics Inc (SRNE) is a sell. selling SRNE stocks now will result in a potential gain of 14060843.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.9% - 8.7% | 6.8% |
| Long-term Growth Rate | 3.0% - 4.6% | 3.8% |
| Fair Price | (508,159.44) - (22,627.33) | (43,208.66) |
| Upside | -165362753.8% - -7363369.2% | -14060843.3% |